 So the frontline quadruplet treatment with Isotuximab carphosomeblenolidomide and dexamethasone was investigated in the concept trial, a trial for newly diagnosed high risk myeloma patients, only high risk patients, however, both transplant eligible and transplant non-eligible. And I had a great pleasure and privilege to present the data today, virtual. And so this combination of a monoclonal anti-CD38 antibody, the Isotuximab with carphosomeblenolidomide and dexamethasone is in the trial given in induction, consolidation and also maintenance, however, the maintenance is without the dexamethasone. And transplant eligible patients undergo also a high-risk myeloma or pathological sensor transplantation. So here at the ESCO meeting, we reported of the first 50 patients on response during the six cycle, I said, KRD induction. And what we saw is that we had in those 50 patients 100% over response rate, 90% of patients achieved equal amount than a VGPR and 46% of patients achieved a CR or stringent CR. We had also done an MRD assessment in 33 patients during induction in the transplant arm. And of those 20 were at this time at this early time MRD negative. We think that these are really promising data. The trial just completed recruitment and we will continuously work on the data and report on the data, but we are very encouraged also by the feedback of the colleagues. So the Isotuximab KRD rate and we saw very favorable toxicity profile. The main toxicities were hematologic with a predominant neutropenia full of balumphopenia and leukemia. However, grade 3 or 4 thrombocytopenic events were rare with over 14%. Regarding non-hematological toxicities, we saw only very few grade 3 or 4 toxicities, especially peripheral neuropathy, which is often a hamper even in VTD or VRD arrangements. Those rates were low. We had an overall rate, all grades of peripheral neuropathy of 16%. We had no death on study so that the toxicity profile was really favorable. We don't know. I personally think that all the data now coming out on quadruplet treatment are really showing that what we currently know, it should be the standard of care. Because we see that we can induce high rates of MRD negativity and we know that we can translate MRD negativity in a better progression free, but even more in a better overall survival in our myeloma patients. I think we have the unmet need to establish that and I think it hopefully justifies also the effort. Belanta Maffodotin is an immuno conjugate. It's directed against the BCMA, the B-cell maturation antigen, as also other constructs are, especially the CAR-T cells. The drug was first investigated in very refractory patients and showed promising results, especially regarding induction of deep responses in a late stage of the disease. Here, the first combination data are shown with a combination with Bordesumab and Bexamantazone. As it is usual, there has to be found a dose and this is a dose escalation trial of this combination treatment. The patient population is still limited in a number, but we see very encouraging results with an over-response rate of close to 80%. In the cross trial comparisons as complicated as they are, is that superior to Bordesumab and Bexamantazone alone? What we know from a long, long time. As many patients are now receiving the immunomodulatory drugs, especially Lidomite during first line and very long, we have a need for an imit-free treatment combinations which are effective. I think we have to expect here very promising data when we oversee more patients. I personally also treated now a number of patients with Ballantemab and Bexamantazone. It's a very distinct and unique toxicity of this drug, or Brexmas also. But we learn very much to handle this with fixed eye drops, can't use supportive care. The good news is that the corneal toxicity normally is absolutely reversible. The impact on life quality varies. Some patients who have objective changes when they are examined by an ophthalmologist don't even have any symptoms, other have symptoms. So we learn that the drug can be paused and can also be reduced. So I think overall it's a new toxicity, but it's normally very well to handle. So this tourmaline trial investigates the exasomab maintenance in transplant non-alligable patients, whereas we have already the full publication of investigating the drug after transplant, Hytosmethylalananthotoloxidate. So those were non-transplant-alligable patients having had a fixed time treatment as a first-line treatment and then underwent exasomab or placebo in this randomized trial. So it's a placebo control trial which makes it unique. And the exasomab maintenance resulted in a 34% reduction in the risk of progression, and this was statistically significant. However, we have now also to consider that most of the novel regimens as standard of care regimens in treatment of newly diagnosed transplant non-alligable myeloma patients are continuous treatment regimens. So in this whole context, this is an important trial with an important message. However, we have currently many different treatments available and fixed duration treatment is normally not anymore performed regularly in this setting. Honestly, I don't know if it will in the transplant-alligable setting. It seemed to be less effective than the linalidomide maintenance. However, there are patients who do not tolerate linalidomide and there are countries where linalidomide is not available. So per se it would be good to have an alternative. How that will be translated in the real life, this will be the decision of the authorities, the competent authorities and currently I do not know what we have to expect in this manner. This is a very interesting rack. It took us all a long time to understand what the immunomodulating agents are doing and the full mechanism is still, I think, not fully understood. However, we do know a lot and we do know the cascade or the main signal cascade where they are acting in the cell. And the cell modes are drugs where it was possible to enhance the affinity of the drug to the target so making them more effective and without adding toxicity per se. So this makes it very attractive. And the trial now presented that were the first trial of the CC480 cell mode with very promising overall response rates of close to 50% in a pre-treated patient population show that the drug is effective, that it's well tolerated. And I think it's a natural thing that we are dealing now for more than a decade with teledomide and nanolidomide. And this is now the next generation which was just made more effective like we have this in chronic myeloid leukemia when we have the second generation tyrosine kinase inhibitors. And we now have to establish those treatment combinations and do the appropriate trials and we will see if they then will substitute the first generation of immunomodulating agents. So the Boston trial is a randomized trial, one-to-one randomization between salinexor, bordesum and baximetazone versus bordesum and baximetazone in the well-known established relaxed treatment scheme. And the trial showed with a primary endpoint of progression-free survival including roughly 400 patients that the addition of salinexor, so the extension of the bordesum and baximetazone doublet towards a triplet increased the efficacy so that the progression-free survival in the salinexor group was close to 14 months compared to 9.5 months in the standard arm which was the hazard ratio of 0.7, so a clear superiority. What is very interesting is that the once weekly application of bordesum in this experimental arm and the once weekly application of salinexor was not only convenient but resulted also in a market and significant reduction in perperoneuropathy. We know that salinexor has some side effects which are nausea, fatigue, other potential non-hematologic side effects. In this once weekly schedule they were mostly mild and so that the tolerability obviously is better as in the first published data on highly refractory multiple myeloma patients. Again, here as I said before this is an important image-free triplet when images are given regularly during first-line treatment for a long time. I personally think that the CAR-T cell data were again very intriguing and as we saw at the ASH meeting, we saw here also great data especially out of the CAR-D2 trial but also with the other CAR-T constructs there were three oral presentations and I think this is still a great achievement and these treatment strategies will definitely bring us forward in treatment of multiple myeloma.